EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Population pharmacokinetic analysis of lamivudine (3TC) in HIV-exposed neonates and pediatric participants living with HIV-1 from the IMPAACT 2019 and PETITE studies

Ana Carolina Conchon Costa iD, Yu-Wei Lin iD, Hardik Chandasana iD, Jon Collins iD, Adrie Bekker iD, Tim R Cressey, Kristina M Brooks iD, Isabelle Deprez, S Y Amy Cheung, Mark Bush iD, Rashmi Mehta iD, IMPAACT 2019 Team und 1 weitere

Antimicrobial Agents and Chemotherapy · 10.11.2026

DOI: 10.1128/aac.00701-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, online erschienen am 10.11.2026. Verfasst von Ana Carolina Conchon Costa und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, USA. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lamivudine is a nucleoside reverse transcriptase inhibitor widely used in combination antiretroviral therapy for the treatment of human immunodeficiency virus infection. Accurate dose selection in neonates and young children remains challenging because of rapid developmental changes in renal clearance. We updated an existing pediatric population pharmacokinetic (PopPK) model, previously developed using data from 210 participants across five studies, by incorporating a maturation function and integrating pharmacokinetic data from two additional studies, IMPAACT 2019 ( n = 55) and PETITE ( n = 24, all neonates), for a total of 289 participants aged 0.0137 (~5 days) to 19.1 years. Unlike the prior model, which did not include a maturation function, the refined PopPK model incorporates a sigmoid Emax maturation function on clearance (postmenstrual age at which clearance reaches 50% of its mature [adult] value (TM50) 51.4 weeks postmenstrual age; Hill coefficient 4.81), reflecting developmental immaturity of clearance mechanisms in early life. The PopPK model retained a one-compartment structure with first-order absorption and linear elimination. Estimation of allometric exponents for body weight further improved model fit, and inter-individual and inter-occasion variability were included in clearance, volume, and absorption rate constant. Model performance was assessed using standard goodness-of-fit diagnostics and visual predictive checks, which demonstrated good agreement between observed and model-predicted concentrations across the pediatric age and weight range. In conclusion, incorporation of a maturation function on clearance successfully extended the pediatric lamivudine PopPK model to term neonates and infants, with parameter estimates remaining consistent with the original model, supporting model-informed dose selection in this understudied population.

Schlagwörter

Stichwörter der Autor:innen

HIVlamivudinepediatricspharmacometricspopulation pharmacokinetics

Autor:innen und Institutionen

  • GSK, Durham, North Carolina, USA.
  • Certara, Radnor, Pennsylvania, USA.
  • ViiV Healthcare, Durham, North Carolina, USA.
  • Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
  • AMS-PHPT Research Collaboration, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom.

ORCID-Profile: Ana Carolina Conchon Costa, Yu-Wei Lin, Hardik Chandasana, Jon Collins, Adrie Bekker, Kristina M Brooks, Mark Bush, Rashmi Mehta

Zitieren

APA

Costa, A. C. C., Lin, Y. W., Chandasana, H., Collins, J., Bekker, A., Cressey, T. R., Brooks, K. M., Deprez, I., Cheung, S. Y. A., Bush, M., Mehta, R., IMPAACT 2019 Team, & PETITE study Team (2026). Population pharmacokinetic analysis of lamivudine (3TC) in HIV-exposed neonates and pediatric participants living with HIV-1 from the IMPAACT 2019 and PETITE studies. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00701-26

Vancouver

Costa ACC, Lin YW, Chandasana H, Collins J, Bekker A, Cressey TR, et al. Population pharmacokinetic analysis of lamivudine (3TC) in HIV-exposed neonates and pediatric participants living with HIV-1 from the IMPAACT 2019 and PETITE studies. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00701-26

BibTeX
@article{Costa2026,
  author = {Costa, Ana Carolina Conchon and Lin, Yu-Wei and Chandasana, Hardik and Collins, Jon and Bekker, Adrie and Cressey, Tim R and Brooks, Kristina M and Deprez, Isabelle and Cheung, S Y Amy and Bush, Mark and Mehta, Rashmi and IMPAACT 2019 Team, IMPAACT 2019 Team and PETITE study Team, PETITE study Team},
  title = {Population pharmacokinetic analysis of lamivudine (3TC) in HIV-exposed neonates and pediatric participants living with HIV-1 from the IMPAACT 2019 and PETITE studies},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00701-26}
}
Kostenlos starten →